Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Il-Yang Pharm. Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01602952
First received: April 20, 2012
Last updated: March 4, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
No publications provided by Il-Yang Pharm. Co., Ltd.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):